 CHARLOTTESVILLE, VA ACCESSWIRE April 15, 2020 Adial Pharmaceuticals, Inc. NASDAQ:ADIL; ADILW, a clinical-stage biopharmaceutical company focused on the development of treatments for addiction, today announced that U.S. Patent Number 10,619,209, titled Serotonin Transporter Gene and Treatment of Opioid-Related Disorders issued on April 14, 2020. This patent covers the treatment of Opioid Use Disorder by administering the Companys investigational new drug product, AD04, an antagonist of the serotonin-3 receptor 5-HT3, to patients with the LL and TT genotypes, which may be identified by Adials proprietary genetic test. The gene responsible for encoding the serotonin transporter SERT, SLC6A4, located on the chromosome 17q11.1-q12, is the only known gene encoding the serotonin transporter and has a functional polymorphism at the 5-regulatory promoter region, which results in two forms, long L or short S. 